PDF file: 441-2673_C19_Therapeutics_Task_Force_TTF_approved_therapeutics.pdf
OPQ ID: 441-2673
Session: 441
Question number: Q-2673
Sessional paper: Q-2673
Title: C19 Therapeutics Task Force, TTF, approved therapeutics
Short description: 
Topic: public health
Identified concern: 
Keywords: 
Agencies: HC, PHAC, PSPC, ISED
Date asked: 2024-05-02
Date tabled: 
Submitted by: Mrs. Wagantall (Yorkton—Melville)
Reply by: Minister of Health
Responded by: Mr. Yasir Naqvi
Pages: 9
Status: not processed
Alert: yellow
Questions asked: 13
Questions answered: 2
Percent responded: 15%
Referenced sources: (none extracted)
Referenced links: (none extracted)
Official link: https://www.google.com/search?q=Q-2673+ourcommons.ca
PDF URL: https://ivim.ca/foi/opq/r/441-2673_C19_Therapeutics_Task_Force_TTF_approved_therapeutics.pdf
TXT URL: https://ivim.ca/foi/opq/r/441-2673.txt
Original filename: Q-2673 (Order) C19 Therapeutics Task Force, TTF, approved therapeutics.pdf
Local source path: C:\Users\Dmitry\Documents\CODES\OPQ-App\data-raw\OPQ\ALL OPQ TO DATE\2022\Q-2673 (Order) C19 Therapeutics Task Force, TTF, approved therapeutics.pdf
Machine extracted at: 2026-06-30 12:58:27

References / links:
(none extracted)

Machine notes:
(none)

Question text preview:
With regard to the COVID-19 Therapeutics Task Force (TTF) who oversaw submissions for grant funding from Innovation, Science and
Economic Development Canada (ISED)’s Strategic Innovation Fund: (a) in total, how many projects were considered for funding;
(b) with respect to the projects which were funded, (i) how many received funding, (ii) how much funding was allocated per project, (iii) which drugs were being investigated per each approved project, (iv) what was the total amount of funding granted for the approved projects;
(c) with regard to the projects which were not approved for funding, what recommendations were made to them;
(d) with regard to the therapeutics which were recommended for purchase, (i) what were these therapeutics, (ii) were these therapeutics purchased, (iii) what was the implementation plan, (iv) if there was no plan, why not;
(e) were the drugs Ivermectin or Hydroxychloroquine considered by the TFF;
(f) if the answer to (e) is affirmative, what were their recommendations and how did they arrive at them;
(g) who were the members of the TTF;
(h) were any of the members pharmacists, pharmacologists, or toxicologists;
(i) what were the members' conflicts of interest;
(j) did any of the members withdraw from the task force prior to its conclusion;
(k) if the answer to (j) is affirmative, who left early and why;
(l) regarding the document entitled “HEALTH CANADA/ PUBLIC HEALTH AGENCY OF CANADA MEMORANDUM TO THE MINISTER OF HEALTH,
Meeting with the COVID-19 Therapeutics Task Force” dated February 24, 2021, and signed by the President of the Public Health Agency of
Canada and the Deputy Minister of Health, which reads that “At the previous meeting TTF members expressed concern that their mandate was ending.
TTF members were specifically concerned about what they felt was insufficient attention to therapeutics, failures of implementation, and the need to be forward looking for surveillance of upcoming therapeutic opportunities.
It is expected that TTF members will raise these concerns to you”, (i) what concerns were raised to the signee, (ii) what documents were provided with respect to expressing those concerns; and (m) when and why was the TTF mandate ended?